Angeli A, Bisbocci D, Orlandi F, Paccotti P, Tabasso R, Tamagnone C, Lavezzaro G C
Clin Endocrinol (Oxf). 1981 Dec;15(6):555-65. doi: 10.1111/j.1365-2265.1981.tb00701.x.
To study effects on pituitary-adrenocortical activity of a sustained block of angiotensin II formation, six 'drug-resistant' patients with essential hypertension were studied before and during treatment with an inhibitor of the angiotensin-converting enzyme (Captopril, SQ 14,225). The drug was given in increasing doses (100-400 mg/day) for 2 weeks whilst patients received a moderately restricted sodium intake (60-80 mmol/day). Immunoreactive ACTH, cortisol, aldosterone, plasma renin activity (PRA) and the activity of the angiotensin-converting enzyme (ACE) were measured in blood samples drawn at 0800-0900 h. Urinary excretion of cortisol and aldosterone were measured in 24-h urine collections. Further information on pituitary-adreno-cortical function was obtained by measuring serial plasma corticosteroid levels after submaximal stimulation with a synthetic ACTH preparation. ACTH and cortisol did not change an observation which does not support the hypothesis that glucocorticoid activity is influenced by a decrease in plasma angiotensin II concentrations.
为研究持续阻断血管紧张素II形成对垂体-肾上腺皮质活动的影响，对6例“耐药性”原发性高血压患者在使用血管紧张素转换酶抑制剂（卡托普利，SQ 14,225）治疗前及治疗期间进行了研究。在患者接受适度限钠饮食（60 - 80 mmol/天）的同时，以递增剂量（100 - 400 mg/天）给予该药物，持续2周。于上午0800 - 0900采集血样，测定免疫反应性促肾上腺皮质激素（ACTH）、皮质醇、醛固酮、血浆肾素活性（PRA）及血管紧张素转换酶（ACE）活性。收集24小时尿液，测定皮质醇和醛固酮的尿排泄量。通过用合成ACTH制剂进行次最大刺激后测定系列血浆皮质类固醇水平，获取有关垂体-肾上腺皮质功能的更多信息。ACTH和皮质醇未发生变化，这一观察结果不支持糖皮质激素活性受血浆血管紧张素II浓度降低影响的假说。
